AI brief of an SEC Form 8-K · Kiniksa Pharmaceuticals International, plc (KNSA)

Kiniksa Q3 revenue rises 58% to $286.0 million; raises 2026 ARCALYST sales guidance

Positive Impact 4 of 5 earnings Written later

Kiniksa reported third-quarter 2026 total revenue of $286.0 million, up from $180.9 million a year earlier, and net income of $47.3 million, compared with $18.4 million. The company raised its 2026 ARCALYST net product revenue expectation to $1.045 billion to $1.050 billion, from $980 million to $995 million previously, and expects its current operating plan to remain cash flow positive on an annual basis.

Key points

  • Q3 2026 revenue was $286.0 million, compared with $180.9 million in Q3 2025.
  • Q3 2026 net income was $47.3 million, or $0.56 per diluted share, compared with $18.4 million, or $0.23 per diluted share, a year earlier.
  • 2026 ARCALYST net product revenue guidance was raised to $1.045 billion to $1.050 billion from $980 million to $995 million.
  • As of September 30, 2026, the company had $568.8 million in cash, cash equivalents and short-term investments and no debt.

The filing

CompanyKiniksa Pharmaceuticals International, plc (KNSA)
Form8-K, current report
Filed with the SECOct 27, 2026, 7:32 AM ET
Accession number0001730430-26-000037

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 27, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.